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Red Blood Cells as Redox 
Modulators in Hemolytic Anemia
Eitan Fibach and Mutaz Dana
Abstract
The oxidative status of cells, representing the balance between prooxidants 
and antioxidants, is involved in their normal physiological functioning, such 
as signal transduction, proliferation, and differentiation. When the prooxidant 
activity overrides the antioxidative capacity oxidative stress occurs. Chronic 
oxidative stress causes cytotoxicity and organ failure. As such, it is believed 
to play a role in various pathologies, including the hemolytic anemias. In this 
review, we suggest that red blood cells (RBC), in addition to their primary role 
as oxygen carriers, function as redox modulators. In the RBC, various systems 
afford it with antioxidative capacity that, in addition to balancing its own redox 
state, can provide antioxidative protection to the cellular and intracellular milieus 
throughout the body. Their vast number, mobility, occurrence throughout the 
body, and renewability make them good candidates for this function. A decrease 
in their number (anemia) or function due to oxidative stress may exacerbate the 
symptoms of many diseases by failing to neutralize oxidative stress. However, 
correcting anemia, e.g., by repeated RBC transfusions or iron supplementation, 
may increase the iron load, which, in turn, causes oxidative stress. This situation 
suggests that the status of both iron and redox should be monitored during treat-
ment, using RBC as bioindicators.
Keywords: red blood cells, hemolytic anemia, thalassemia, oxidative stress,  
flow cytometry
1. Introduction
The redox status of cells is crucial for normal physiological functioning; how-
ever, when the prooxidant activity overrides the antioxidative capacity (AOC), 
oxidative stress occurs. Chronic oxidative stress causes cytotoxicity and organ 
failure. As such, it is believed to play a role in many diseases, such as cardiovascular, 
thromboembolic and neurodegenerative disorders, as well as aging [1].
In this review, we suggest that RBC, in addition to their primary role as 
oxygen and CO2 carriers, functions as redox modulators. Various RBC systems 
afford them with AOC that, in addition to balancing their own redox state, 
can provide antioxidative protection to the cellular and intercellular milieus 
throughout the body. Their vast number, mobility, and occurrence throughout 
the body and renewability make them good candidates for this function. A 
decrease in their number (anemia) or function may exacerbate the symptoms 
of many diseases by failing to neutralize oxidative stress. However, correcting 
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anemia, e.g., by repeated RBC transfusions or by iron supplementation, may 
increase the iron load, which, in turn, causes oxidative stress. This situation 
suggests that the status of both iron and redox should be monitored during 
treatment, using RBC as bioindicators.
2. Oxidative stress and its involvement in pathology
The cellular redox status represents the balance between generation of free 
radicals, such as the reactive oxygen species (ROS) and reactive nitrogen spe-
cies (RNS), and the ability to detoxify them or to repair their resultant damage 
by antioxidants, such as the reduced glutathione (GSH), the major intracellular 
scavenger of ROS. ROS are generated in cells mainly during energy production: In 
the mitochondria, about 2% of the total oxygen (O2) consumption results in the free 
radical superoxide anion (O2
−) [1]. While not particularly reactive, superoxide can 
act as a reductant toward divalent metal ions, mainly iron and copper, and can react 
with itself by spontaneous or enzymatic (e.g., by the reducing enzyme superoxide 
dismutase, SOD) dismutation to form hydrogen peroxide (H2O2). The latter is a 
mild oxidant, but in the presence of divalent metals, it can generate the reactive 
hydroxyl (˙OH) radical.
In mature RBC, which are devoid of mitochondria, the hemoglobin (Hb) is the 
major source of ROS generation [2]. The heme iron, which is in the Fe(II) ferrous 
state in the oxygenated Hb, is oxidized to the Fe(III) ferric state in metHb—a 
reaction that normally occurs at a rate of about 3% of the Hb per day. This process 
results in the production of superoxide that in turn generates hydrogen peroxide 
and oxygen as products of dismutation by SOD [3]. The metHb is then restored 
back to oxyHb by the NADH-cytochrome b5 reductase [4].
An additional pathway of oxygen to superoxide reduction is by nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidases. Phagocytic cells, such as 
polymorphonuclear (PMN) neutrophils and macrophages, have an NADPH oxidase 
complex that generates ROS as part of the innate immune response to infection. 
Non-phagocytic cells contain NADPH oxidases that generate ROS, at lower levels 
than phagocytes, for signaling responses [5]. ROS can also arise as the indirect by-
product of enzymatic activities, such as that of monooxygenases (e.g., cytochrome 
P450) [6].
RNS originate from the gaseous molecule nitric oxide (NO). The latter is syn-
thesized by constitutive or inducible nitric oxide synthase enzymes by oxidation of 
L-arginine to L-citrulline. NO can react rapidly with the superoxide anion to form 
the oxidant peroxynitrite (ONOO−), nitrogen dioxide (NO2), nitroxyl (HNO), and 
nitrosonium cation (NO+) (for review see [7]).
The cellular prooxidants are tightly controlled by restricting the magnitude and 
the location of their generation and by elaborating antioxidant mechanisms that 
scavenge their excess and correct their toxic consequences (for review see [1]). In 
addition to these intracellular antioxidant mechanisms, extracellular mechanisms 
function as well. For example, the blood serum contains many molecules with AOC 
such as bilirubin, albumin, ascorbic acid, as well as diet-derived antioxidants such 
as polyphenols.
Under certain conditions, excess oxidants my override the AOC and generate a 
state of oxidative stress. This may occur due to external factors (e.g., certain food 
components, air pollution, sun exposure, environmental radiation, as well as radio- 
and chemotherapeutic regimes) or internal factors such as various pathological 
circumstances (e.g., inflammation, iron overload, Hb instability). Excess ROS react 
quickly with bio-molecules such as the DNA, proteins, and lipids, interfering with 
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cellular functions. As such, even if it is not the primary etiology, oxidative stress is 
believed to mediate the symptoms of many diseases, such as cancer, atherosclerosis, 
diabetes, cardiovascular, thromboembolic and neurodegenerative disorders, as well 
as physiological aging [1].
3. Hemolytic anemia
We have studied oxidative stress in hemolytic anemias [8]. The anemia in 
these hereditary or acquired diseases is the result of augmented destruction 
(hemolysis) of mature RBC and their immature progenitors/precursors that is 
not balanced by compensatory overproduction. Among these diseases are: (I) The 
hemoglobinopathies—caused by mutations in the globin genes, leading to insuf-
ficient production (thalassemia) or production of aborted (sickle cell disease) 
globin chains [9]. (II) RBC membrane/cytoskeletal disorders such as hereditary 
spherocytosis, elliptocytosis, and stomatocytosis—caused by mutations in genes 
leading to abnormal RBC shape and propensity for hemolysis [10]. (III) Inherited 
enzymatic defects in RBC such as glucose-6-phosphate dehydrogenase (G6PD) 
deficiency and pyruvate kinase deficiency. G6PD is a key enzyme of the pentose 
pathway (hexose monophosphate shunt) which supplies NADPH—a reducing 
agent that is important for the regulation of the redox state, especially in RBC [11]. 
Patients with G6PD deficiency exhibit hemolytic anemia in response to infection 
and certain medications or foods. (IV) Paroxysmal nocturnal hemoglobinuria—a 
clonal disease caused by an acquired somatic mutation in the phosphatidylinositol 
glycan complementation class A gene. This gene encodes the enzyme responsible for 
the first step in the production of the glycosylphosphatidylinositol anchor, by which 
various proteins are linked to the plasma membrane. In this disease, the mutation 
occurs in a hematopoietic stem cell and is expressed in its progeny, affecting various 
membrane proteins including the complement (C′) inhibitors: CD55 (decay-accel-
erating factor) which inhibits the C3 component of the C′, and CD59 (membrane 
inhibitor of reactive lysis) which inhibits terminal C′ components (C5b-9) from 
forming the hemolytic membrane pore [12]. This leads to hemolysis and platelet 
activation, leading to anemia and to venous thrombosis, respectively [13]. (V) 
Congenital dyserythropoietic anemias—a heterogeneous group of diseases char-
acterized by anemia due to abnormalities of erythroid precursor cells and reduced 
erythropoiesis [14]. (VI) Autoimmune hemolytic anemia such as ABO mismatch 
transfusion reaction and severe idiopathic autoimmune hemolytic anemia—caused 
by autoantibodies against antigens expressed on the surface of RBC. Once formed, 
these antibodies bind to the surface of RBC marking them for destruction through 
C′-mediated lysis (intravascular hemolysis) and/or Fc-mediated phagocytosis 
(extravascular hemolysis). Autoimmune hemolytic anemia can occur alone, but is 
often seen in association with other autoimmune diseases, cancer, drug treatment, 
transfusion, and pregnancy. (VII) Myelodysplastic syndromes (MDS)—diverse 
conditions that involve ineffective production (dysplasia) of hematopoietic cells. 
The patients often develop severe anemia and require frequent blood transfusions. 
In most cases, the disease worsens, and the patient develops cytopenias due to pro-
gressive bone marrow failure. In about one third of patients, the disease transforms 
into acute myelogenous leukemia, usually within months to a few years.
Although oxidative stress is not the primary etiology of these diseases, except for 
G6PD deficiency, it mediates their symptoms, including anemia, recurrent infec-
tions, and thromboembolic complications [8]. The main causes of oxidative stress 
in these diseases are: (I) Degradation of abnormal Hbs in the mature RBC and their 
precursors (in the hemoglobinopathies), leading to the production of hemichromes 
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and eventually to release of heme and iron. (II) Iron overload caused by frequent 
blood transfusions and increased iron uptake [15]. Usually, iron uptake in the gut as 
well as its mobilization from storage cells, regulated by hepcidin, is downregulated 
by iron excess [16]. It these diseases, where the body attempts to compensate for 
the anemia by over production of new RBC (“ineffective erythropoiesis”), iron is in 
high demand. To ensure sufficient iron uptake, the developing erythroid progeni-
tors produce factors that inhibit hepcidin production, thus overriding the regulat-
ing effect of hepcidin. (III) Iron-containing compounds (Hb and hemin) which 
are released by intravascular hemolysis can also add to the iron load and further 
aggravate the hemolysis [17]. In the absence of specific mechanisms for disposal of 
excess iron, under these conditions iron accumulates. Iron overload increases ROS 
generation by catalyzing the Haber-Weiss/Fenton biochemical reactions [3, 18].
4. RBC as redox modulators
The main function of RBC is oxygen transport, for which they have evolved 
efficient nonenzymatic and enzymatic antioxidative systems for protection against 
oxidizing substances to which they are exposed. The nonenzymatic systems include 
reduced glutathione, thioredoxin, ascorbic acid, and vitamin E. The most important 
antioxidant enzymes include SOD, thioredoxin reductase/peroxiredoxin system, 
catalase, glutathione peroxidase, glutathione reductase, plasma membrane oxidore-
ductases, and the metHb reductase/NADH/glycolysis system that maintains Hb in a 
Fe(II)-active form [19].
Although these systems mainly serve the RBC own requirements, it seems that 
since they are produced in excess they can be utilized for antioxidant protection of 
other cells, at least under conditions of oxidative stress. This function may affect 
the intra- and extracellular milieus throughout the body, especially of cells in the 
circulation and in the perivascular tissues (endothelial cells).
Several characteristics, in addition to their extra reducing power, make RBC 
ideal candidates to serve as redox mediators. These include their vast number, 
mobility, and occurrence throughout the body. The consequence of their antioxi-
dative activity could be oxidative damage to the RBC themself, facilitating their 
erythrophagocytosis, degradation, and detoxification of their oxidized constituents 
by macrophages in reticuloendothelial systems, mainly the spleen and the liver. 
These damaged/old RBC are replaced by new RBC that are continuously formed in 
the bone marrow.
A “bystander” effect of cells on the oxidative status of other neighboring cells 
has been described previously in other circumstances of oxidative stress induced by 
ionizing or photoradiation [20, 21].
4.1 Proofs of the concept
The concept of the RBC protective role was first introduced by Fazi et al. 
[22]. They showed that RBC are able to inactivate harmful xenobiotics, including 
1-chloro-2,4-dinitrobenzene, by conjugation with glutathione and suggested that it 
may be possible to treat xenobiotic intoxication by transfusion of GSH-loaded RBC.
Richards et al. have shown that RBC can protect endothelial cells from PMN- 
induced damage [23]. PMN exert their antibacterial effect by generating a burst of 
ROS (respiratory burst) in response to toxins released by phagocytosed bacteria. 
These ROS not only kill the bacteria but also damage the PMN themselves and 
other neighboring cells (inflammation). The respiratory burst can be reproduced 
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in vitro by incubating PMN with phorbol myristate acetate (PMA). In their study, 
51Cr-labeled endothelial cells were incubated with PMA-triggered PMN. Damage to 
the endothelial cells was measured by the release of 51Cr into the incubation medium. 
Adding RBC to the mixture reduced the damage dose-dependently. Analyzing the 
RBC following the incubation, revealed reduced levels of 2,3-diphosphoglyceric acid 
and glutathione, and increased levels of the oxidation products malondialdehyde and 
metHb. These results indicated that these RBC are under oxidative stress compared 
with RBC incubated alone or with non-triggered PMN. The authors suggested that 
RBC can provide antioxidant protection to other tissues in vivo [24].
We have studied the effect of RBC on the oxidative status of other cells by 
measuring oxidative parameters by flow cytometry. Following pulse-labeling of 
cells with the probe 2′7′-dichlorodihydrofluorescindiacetate, their fluorescence 
was proportional to their ROS content. The increase in their fluorescence after 
washing indicated their rate of generation of ROS. In our experiments, the labeled 
cells were incubated with RBC derived from either normal donors or patients with 
β-thalassemia. Normal RBC had a dose-dependent decrease effect on ROS genera-
tion, while thalassemic RBC had a much inferior effect [25].
It is well known that thalassemic RBC are under oxidative stress and contain 
more free iron load (the labile iron pool) than normal RBC [26]. To explore this 
condition on their AOC, RBC were exposed to agents that affect their oxidative 
stress or iron overload: normal RBC—to the oxidant hydrogen peroxide or to an iron 
source, ferric ammonium citrate, and thalassemic RBC—to the antioxidant N-acetyl 
cysteine or to the iron chelator, Desferal. The RBC were then mixed with the probe-
labeled cells, and the kinetics of ROS generated by the labeled cells was monitored 
during incubation. The results indicated that oxidants and iron reduced the AOC of 
RBC (Figure 1).
Figure 1. 
The effects of iron overload and oxidative stress on the antioxidative capacity (AOC) of normal and 
thalassemia RBC. The human myeloid leukemia HL60 cells were labeled with 2′-7′-di-chlorofluorescein 
diacetate, washed, and then incubated with 6 × 106/ml RBC from normal or β-thalassemia donors (N = 6 
each). Prior to incubation with cells, the RBC had been treated for 30 min: normal RBC with ferric 
ammonium citrate (FAC), 1 mM, and thalassemic RBC—with the iron chelator, Desferal, 5 mM—thus 
increasing and decreasing iron overload, respectively. Alternatively, normal RBC had been treated with the 
oxidant H2O2, 5 mM, and thalassemic RBCs—with the anti-oxidant N-acetyl cysteine (NAC), 5 mM—thus 
increasing and decreasing oxidative stress, respectively. The cells were then analyzed by a flow cytometer 
(FACS-caliburR; Becton-Dickinson, Immunofluorometry systems, Mountain View, CA, USA). The average 
(mean fluorescence channel) cellular green fluorescence (FL-1), reversely indicating the AOC, of 40,000 
HL60 cells, was determined. In the analysis, RBC were excluded from HL60 cells by gating based on 
forward - and side-light scatter and fluorescence. The results indicate that the AOC of thalassemia RBC was 
significantly lower than that of normal RBC, and that iron and oxidants further decreased it, but it could be 
restored by iron chelation or antioxidants.
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4.2 RBC as oxidants
Oxidative stress, being a common feature of many diseases, affects most cells of 
the body, including the RBC. These diseases involve RBC directly (e.g., thalassemia) 
or indirectly (e.g., diabetes) [27]. We have shown oxidative stress in RBC in all the 
hemolytic anemias [15]. Oxidative stress in RBC diminishing their own AOC, result-
ing in their short survival, but also reduces their ability to protect other cells. Under 
extreme conditions, this situation may turn the RBC into oxidative agents, rather than 
antioxidative agents.
4.3 Probable mechanisms involved in redox protection of RBC
Using artificial vesicles, it has been shown that while hydrogen peroxide readily 
crosses biological membranes, superoxide does it very slowly [28]. Vesicles made of 
RBC membranes allow superoxide to cross through and oxidize cytochrome c in the 
suspending medium within a time-frame consistent with its half-life time [29]. This 
transfer probably occurs via an anion channel since it was inhibited by stilbenes, 
which inhibit the exchange of anions across the membrane. Whether such outward 
flux actually occurs in intact RBC is doubtful. Since RBC contain a large amount of 
SOD [30], it seems unlikely that superoxide made within the RBC would escape both 
the spontaneous and enzymatic dismutations and diffuse across the membrane. In 
contrast, an inward flux could occur. The plasma contains comparatively little SOD 
[31], and superoxides generated outside the RBC might diffuse inward to be scav-
enged by the RBC-SOD. In this fashion, RBC might limit the damage inflicted by 
superoxides produced by blood phagocytes and vascular endothelial cells.
Similarly, RBC provide a mechanism for inactivation of free NO [32]. NO liberated 
from endothelium may be taken up by RBC and inactivated by oxyHb that in turn is 
converted to metHb, while the NO is converted to nitrate to be secreted by the kidneys.
Another RBC redox protective mechanism involves ascorbic acid (AA) (vitamin 
C) [33]. In humans, AA dietary intake is essential for maintaining plasma and 
tissue reductive capacity. It primarily functions to scavenge superoxide anion and 
singlet oxygen, but it also removes other ROS generated by protein-bound redox 
metals and xanthine oxidase. AA itself is oxidized to an AA radical and dehydro 
AA. Human RBC were suggested to possess a two-layered system of redox recy-
cling of low concentrations of the AA radical under minimal oxidative stress and 
a backup system of recycling of large quantities of dehydro AA under increased 
oxidative stress. RBC accumulation of dehydro AA as a result of prooxidative condi-
tions originates in part outside of the RBC during the two-electron oxidation of AA, 
which is subsequently transported reversibly in competition with glucose by the 
type 1 glucose transporters spanning the RBC membrane. Alternatively, dehydro 
AA may be lost altogether by degradation, removing a pool of potentially revers-
ible oxidized AA. Experimental evidence suggests that recycling of AA by the RBC 
significantly add to the AOC of the blood [34].
Still another potential RBC redox protective mechanism is through the release 
of antioxidants and antioxidative enzymes (e.g., SOD and catalase) following 
hemolysis. We have found that hemolysate inhibits ROS generation by cells (unpub-
lished observation). This could also occur following shedding of membrane-bound 
vesicles during the maturation of erythroid precursors in the bone marrow and 
senescence of RBC in the circulation. Both processes are enhanced in hemolytic 
anemias by oxidative stress [35].
Except for direct effects, RBC may affect other cells indirectly. For example, 
diet-derived antioxidant polyamines tend to attach to RBC membranes, resulting in 
a synergistic enhancement of their antioxidative activity [36].
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5. Pathological significance of RBC as redox modulators
The redox-modulating activity of RBC could affect cells and their function 
throughout the body. We have studied their effect on platelets. Hemolytic anemia, 
such as thalassemia, is often associated with high incidence of thromboembolic 
complications (e.g., venous thrombosis and stroke) due to platelet hyperactivation 
and plasma hypercoagulation [37]. Platelet functioning depends on their redox state. 
They have an inherent ability to produce ROS by various pathways—as a by-product 
of the mitochondrial respiratory chain [38] and by the NADH/NADPH oxidase [for 
a review see [39]] produced mainly in the pentose cycle [40]. ROS, along with NO, 
adenosine, and prostacyclins, may play a profound role in the regulation of platelet 
activities [41]. Many studies demonstrated that their functioning during clot 
formation involves ROS; for example, platelet activators, such as thrombin, increase 
ROS generation [42–44].
Oxidative stress in platelets may give rise to two pathological outcomes: (I) 
toxicity, resulting in thrombocytopenia and bleeding and (II) hyperactivation 
resulting in excess clot formation leading to thromboembolic complications. 
Exemplifying the latter is hydrogen peroxide that stimulates their oxidative 
stress [45], and affects their various functions: activation by: (I) arachidonic 
acid and collagen [46]; (II) thrombin and ADP [47–49]; (III) tyrosine phos-
phorylation of the platelet αIIbβ3, an independent platelet activation pathway, 
thereby enhancing their aggregation [50], as well as (IV) through scavenging of 
the platelet- or endothelium-derived NO—thereby decreasing its aggregation-
inhibiting effect [51]. Superoxide can also contribute to late clot growth by 
increasing the bioavailability of ADP and subsequently recruiting additional 
platelets [49].
Since platelets do not carry known specific inherent redox pathology, it is 
reasonable to attribute their oxidative stress, at least in part, to continuous exposure 
to oxidative insults from extra platelet sources, such as their environment, i.e., the 
blood plasma, and neighboring cells - blood cells and the vascular endothelium. 
We have shown that incubation of normal platelets with plasma from thalassemia 
patients, rather than with normal plasma, resulted in their oxidative stress and 
activation [52]. Potential plasma oxidants are iron-containing compounds such as 
non-transferrin-bound iron, ferritin, heme, or Hb, all of which are increased in 
thalassemia patients [47, 53]. Incubation of platelets with iron (ferric ammonium 
citrate), heme (hemin or heme arginate), or Hb stimulated their oxidative stress. 
Moreover, addition of the iron-chelator deferoxamine to thalassemic plasma 
reduced its effect on the platelets’ ROS [52].
Interestingly, thalassemic RBC also increased normal platelet oxidative status. In 
contrast, normal RBC, unless treated with oxidants, decreased it [54]. These results 
suggest that thalassemic RBC, having a higher than normal ROS level, mediate oxi-
dative stress in platelets directly, probably by contact or close proximity [25]. These 
results are compatible with studies showing that platelets could be activated by ROS 
generated by neighboring cells such as RBC, neutrophils [55, 56], fibroblasts, and 
vascular endothelial and smooth muscle cells [39].
RBC might also affect platelets indirectly by a variety of mechanisms: (I) Release 
of iron-containing oxidants into the plasma [46, 57, 58], as mentioned above. (II) 
Release of ROS, e.g., superoxide anions, causing oxidation of low-density lipopro-
tein [59], which, in turn, might activate platelets [60]. (III) Exposure or shedding 
of phosphatidylserine moieties, which act as a procoagulant that amplifies the 
generation of thrombin and thus initiates platelet activation [61]. Thalassemic RBC 
have been shown to carry and shed higher than normal levels of external phosphati-
dylserine [35].
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Other important function of the RBC-AOC is to scavenge and detoxify NO, an 
important vasodilating agent. released  from the vascular endothelial cells [32] and 
by inflamed tissues [62].
The role of RBC as redox modulators can be compromised under pathological 
conditions: when their number decrease (anemia) and when their AOC is defective, 
both of which may co-exist in many diseases. Anemia may elevate oxidative stress 
by reducing the oxygen availability (hypoxia) to tissue cells and by reducing the 
AOC of the RBC.
Various therapeutic modalities may be used to correct anemia:
• Iron supplementation in the case of deficiency.
• Administration of erythropoiesis-stimulating agents such as erythropoietin 
(EPO) in cases of reduced erythropoiesis. This includes patients with chronic 
kidney disease where there is insufficient EPO production due to renal dys-
function, patients with malignancies during the course of chemotherapy, and 
patients with myelodysplastic syndrome. In most of these cases, the treatment 
comprises both EPO and iron supplementation.
• Blood transfusion is used in the event of acute, severe, hemorrhage, or in 
chronic hemolysis. An example of the latter is β-thalassemia major where 
patients are transfused with packed RBC every 3 weeks for their entire life.
Both transfusions and EPO have been used pre- and post-major operative 
procedures that are associated with severe blood loss.
All these therapeutic procedures, on one hand, increase the RBC mass and 
thereby, supposedly, its AOC. On the other hand, iron supplementation and transfu-
sions might increase the iron load leading to oxidative stress in cells, including RBC, 
thus compromising their AOC. For example, multi-transfused thalassemic patients, 
with less severe anemia but higher iron overload, have lower levels of oxidative stress 
(ROS and lipid hydroperoxides) than un-transfused patients, with more severe 
anemia but lower iron overload [63]. In cardiovascular diseases, although there 
is ample clinical evidence for the worsening effect of anemia, RBC transfusions 
or EPO administration were not always effective [64–66]. As for EPO, it has been 
demonstrated to have an antioxidative effect on various cells, including RBC [67], 
and thereby might increase their AOC. The net effect of anemia and iron overload on 
Figure 2. 
The relationship among anemia, its treatment and RBC antioxidative capacity on oxidative stress. Upward red 
arrows indicate an increase; the downward blue arrows indicate a decrease.
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oxidative stress warrants a careful study in transfused and non-transfused patients 
and favors continuous monitoring of the status of iron and oxidative stress during 
these treatments. This complex relationship is graphically summarized in Figure 2.
Some therapeutic protocols are used to reduce the RBC mass (hematocrit). 
Bloodletting (phlebotomy) is used in cases of polycythemia (erythrocytosis), either 
primary (polycythemia vera), familiar, or secondary [68], as well as hereditary 
hemochromatosis—an inheritable disease characterized by iron overload [69]. The 
benefit of this treatment with respect to decreasing the iron load should be weighed 
against its potential reducing effect of the RBC-AOC.
6. RBC as redox bioindicators
The oxidative state of RBC depends on intra-RBC factors such as enzymopahtol-
ogy (e.g., G6PD deficiency), Hb instability (thalassemia and sickle cell disease), 
membrane pathology (hereditary spherocytosis), glucose metabolism [diabetes [27]], 
or extra-RBC factors such as in inflammation. Their oxidative state, in turn, may 
affect their AOC. It was suggested that RBC could be used as bioindicators of prog-
nostic value in clinical practice [19]. They may provide a real-time monitoring of their 
own conditions as well as those in other parts of the body. This is potentially relevant 
to RBC-linked and unlinked pathologic conditions associated with oxidative stress.
6.1 Measurement of the redox status in RBC
Measurement of redox parameters in cells and in body fluids, such as the blood 
plasma, can be accomplished by various methods [3]. These measurements, how-
ever, are not a common practice in the clinic mainly because the methodologies are 
inadequate for the routine clinical laboratory. We have measured redox parameters 
[54, 70], including the labile iron pool [71], in RBC by flow cytometry, a common 
methodology in the clinical setting. Various fluorescent probes have been used. For 
example, ROS were measured by 2′7′-dichlorodihydrofluorescindiacetate, [72]. 
Following free diffusion into cells, this nonfluorescent compound is esterified and 
gets trapped intracellularly as 2′7′-dichlorodihydrofluorescein. ROS, mainly perox-
ides, oxidize it to the fluorescent derivative 2′7′-dichlorodihydrofluorescein that its 
cellular fluorescence is proportional to ROS generation [72].
Several points should be considered using this method: (I) Since ROS are 
short-lived, analyses should be performed on fresh samples. (II) The probes used 
are not specific to a particular ROS—a limitation that does not limit the assessment 
of general oxidative stress. (III) The intracellular probe content depends on the 
experimental settings: the concentration of probe added to the composition of the 
medium and the incubation conditions, such as the temperature. However, it also 
depends on the cellular uptake of the probe and its esterification, which depends 
on the different properties of cells (e.g., activated vs. inactivated, pathological vs. 
normal). To overcome these caveats, we have modified the protocol: Cells were 
pulsed with the probe, washed, and then re-incubated in probe-free medium. The 
kinetics of ROS generation was determined by measuring the cellular fluorescence 
at different times.
The method was validated by determining the effect on RBC fluorescence of the 
ROS-generating agent peroxide, the catalase inhibitor sodium azide, and the ROS 
scavenger N-acetyl cysteine. When normal RBC were compared with RBC from 
β-thalassemia patients, both the basal fluorescence and its kinetics were higher in 
the latter, confirming that thalassemic RBC were under oxidative stress.
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7. Conclusions
The redox state is crucial for physiological functioning of cells, but excess reac-
tive oxygen and nitrogen species causes oxidative stress, which is associated with 
many diseases, including hemolytic anemia. These anemias are characterized by 
accelerated destruction (hemolysis) of mature RBC and their precursors that is not 
balanced by compensatory overproduction. Although oxidative stress is not the pri-
mary etiology of most of these anemias, it mediates many of their symptoms. The 
main function of RBC is oxygen transport, for which they have evolved efficient 
nonenzymatic and enzymatic antioxidative systems for protection against oxidiz-
ing substances to which they are exposed. These systems serve mainly the RBC 
requirements, but may influence other neighboring cells as well, making the RBC 
antioxidative protective agents of the cellular and intracellular milieus throughout 
the body. Their vast number, mobility, occurrence throughout the body and renew-
ability make them good candidates for this function. A decrease in their number 
(anemia) or function may exacerbate the symptoms of many diseases, including 
hemolytic anemias, by failing to neutralize oxidative stress. However, correcting 
anemia, e.g., by repeated RBC transfusions or iron supplementation, may increase 
the iron load, which, in turn, causes oxidative stress. This situation suggests that the 
status of both iron and redox should be monitored during treatment, using RBC as 
bioindicators and using flow cytometry multiparameter analysis.
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